Cargando…

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients

Different mechanisms lead to immune checkpoint inhibitor (ICI) resistance. Identifying clinically useful biomarkers might improve drug selection and patients’ therapy. We analyzed the soluble immune checkpoints sPD1, sPDL1, sLAG3, and sTIM3 using ELISA and their expression on circulating T cells usi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Machiraju, Devayani, Wiecken, Melanie, Lang, Nina, Hülsmeyer, Ingrid, Roth, Jasmin, Schank, Timo E., Eurich, Rosa, Halama, Niels, Enk, Alexander, Hassel, Jessica C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158029/ https://www.ncbi.nlm.nih.gov/pubmed/34104542 http://dx.doi.org/10.1080/2162402X.2021.1926762

Ejemplares similares

Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)
por: Hassel, Jessica C., et al.
Publicado: (2022)

Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma
por: Machiraju, Devayani, et al.
Publicado: (2023)

Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
por: Machiraju, Devayani, et al.
Publicado: (2021)

Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells
por: Strobel, Sophia B., et al.
Publicado: (2021)

Immunotherapies for the Treatment of Uveal Melanoma—History and Future
por: Schank, Timo E., et al.
Publicado: (2019)

Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
por: Strobel, Sophia B., et al.
Publicado: (2021)

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
por: Machiraju, Devayani, et al.
Publicado: (2023)

TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma
por: Strobel, Sophia B., et al.
Publicado: (2022)

Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival
por: Schank, Timo E., et al.
Publicado: (2021)

Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
por: Salzmann, Martin, et al.
Publicado: (2022)

The next age of immunotherapy: optimisation, stratification and therapeutic synergies
por: Halama, Niels
Publicado: (2018)

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)
por: Hassel, Jessica C., et al.
Publicado: (2017)

Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma
por: Zhang, Xin-Wen, et al.
Publicado: (2022)

S100 as Serum Tumor Marker in Advanced Uveal Melanoma
por: Salzmann, Martin, et al.
Publicado: (2023)

Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
por: Hassel, Jessica C.
Publicado: (2021)

A New Serum Macrophage Checkpoint Biomarker for Innate Immunotherapy: Soluble Signal-Regulatory Protein Alpha (sSIRPα)
por: Vladimirova, Yoanna V., et al.
Publicado: (2022)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy
por: Sibilio, Pasquale, et al.
Publicado: (2022)

Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2021)

Distinct immune-effector and metabolic profile of CD8(+) T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors
por: Benesova, Karolina, et al.
Publicado: (2022)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma
por: Xia, Daniel, et al.
Publicado: (2018)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Alternative Checkpoints as Targets for Immunotherapy
por: Pant, Ayush, et al.
Publicado: (2020)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
por: Buder-Bakhaya, Kristina, et al.
Publicado: (2018)

Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
por: Teige, Ingrid, et al.
Publicado: (2019)

γδ T cells: origin and fate, subsets, diseases and immunotherapy
por: Hu, Yi, et al.
Publicado: (2023)

Immune checkpoints and immunotherapy for colorectal cancer
por: Singh, Preet Paul, et al.
Publicado: (2015)

Immune checkpoint signaling and cancer immunotherapy
por: He, Xing, et al.
Publicado: (2020)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

Resistance to Checkpoint Inhibition in Cancer Immunotherapy
por: Barrueto, Luisa, et al.
Publicado: (2020)

Emerging phagocytosis checkpoints in cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023)

Identification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma
por: Gondois-Rey, Françoise, et al.
Publicado: (2021)

Quality of life, treatment satisfaction and efficacy of non-biological systemic therapies in patients with plaque psoriasis: study protocol for a prospective observational study
por: Fink, Christine, et al.
Publicado: (2017)

Advanced Malignant Melanoma: Immunologic and Multimodal Therapeutic Strategies
por: Halama, Niels, et al.
Publicado: (2010)

Acute low back pain as infusion-related reaction to monoclonal antibodies
por: Majenka, Pawel, et al.
Publicado: (2023)

Editorial: Soluble immune checkpoints: Novel physiological immunomodulators
por: Riva, Antonio
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mrepr3i6n3hhamjloi9u0kaiqs